PML and BANP

  • Number of citations of the paper that reports this interaction (PMID 20075864)
  • 10
  • Data Source:
  • BioGRID (pull down, affinity chromatography technology)

PML

BANP

Gene Name promyelocytic leukemia BTG3 associated nuclear protein
Image No pdb structure
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9 77 interactors: ADAM15 ALAS2 BAG5 BTG3 C1orf94 C22orf39 C6orf165 CAMK2D CCDC26 CEP76 COL10A1 DCDC2B DNAJA4 EPHA10 FAM117B FAM120C FAM71C FAM90A1 FHL2 FOXM1 FOXR1 GFM2 HMGB3P1 ISCU L3MBTL3 LACE1 LENG1 LGALS14 LINC00152 LINC01547 LMO2 LMO3 LMO4 LSM2 MAP2K1 MAX MIR4435-1HG MRPL28 MVP NEDD9 NRIP2 PHF21A PID1 PIM1 PML POGZ POLDIP3 POLR2L PPIB PPIC PPIF PRKAB2 PRKCH PRPF39 PSMD9 RAB3IP RBM39 RBPMS RIMS3 SH3RF2 SLC16A3 SNRPB SP2 SPACA6P TERF2 TERF2IP TNXB TOX4 TP53 TRAF2 TRAF4 TROAP ZC2HC1C ZMIZ2 ZNF471 ZNF488 ZNF581
Entrez ID 5371 54971
HPRD ID 00023 16538
Ensembl ID ENSG00000140464 ENSG00000172530
Uniprot IDs P29590 B3KM38 B4DE54 Q8N9N5 Q9NSS6
PDB IDs 1BOR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Difference) ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Intersection) ?